The clinical trials below are available in the specialty you selected. Choose a different specialty.

Drug Study for Patients with Genotype 1 Chronic Hepatitis C Infection
Patients with genotype 1 chronic hepatitis C infection are needed to participate in a study that examines the effectiveness of a study drug called IDX184 when given in combination with ribavirin (RBV) and pegylated interferon (Peg-IFN). (REF# 20794)

Study of ANA598 Administered in Combination with Pegylated Interferon and Ribavirin for Untreated Hepatitis C Patients
Untreated hepatitis C patients are needed for a trial to test the safety and effectiveness of ANA598. (REF# 19017)

Study of PEG-rIL-29 Administered in Combination with Ribavirin for Untreated Hepatitis C Patients
Patients with hepatitis C are needed for a trial to study the safety and effectiveness of different doses of PEG-rIL-29 when given with the standard dose of ribavirin, compared to the standard dose of peginterferon alfa-2a (PEGASYS®) given with ribavirin. (REF# 20033)

Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Adults with nonalcoholic fatty liver disease are needed to participate in an observational study. (REF# 20074)

Continuous Interferon Delivery via the Medtronic Paradigm® Pump Infusion
People with the hepatitis C virus are needed for a clinical trial examining continuous interferon delivery with the Medtronic Paradigm Pump. (REF# 18025)

Study of Acid Reflux in Children with Asthma
Physicians at the Duke Asthma Clinical Research Center (ACRC) are studying acid reflux (GER) and asthma in children. (REF# 0739)

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
Patients with non-alcoholic fatty liver disease are needed for this study. (REF# 6196)

Hepatitis Alcohol Reduction Team (Hep ART)
If you have hepatitis C and consume alcohol of any kind, you may be eligible to participate in this study. (REF# 9188)

NRL972 in Patients with Liver Disease
This is an open-label study for patients suspected of having non-alcoholic fatty liver diseas (NAFLD) and undergoing liver biopsy. (REF# 2422)

A Study of PEGASYS (Peginterferon Alfa-2a) Plus COPEGUS (Ribavirin) With or Without Actos (Pioglitazone) in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
The purpose of this study is to see how well Pegasys®, in combination with Copegus®, with and without Actos®, will work to treat chronic hepatitis C (CHC) and insulin resistance. (REF# 3650)

Page 1 2 of 2